The ultimate embodiment of an extracorporeal closed-loop blood-glucose control system will be a portable de- vice consisting of three components: a continuous glucose monitor (CGM), a continuous subcutaneous (SC) drug infusion device (e.g. an insulin pump), and a control algorithm. The control algorithm links the other two com- ponents by receiving the glucose data stream from the CGM, making a therapeutic decision based on that data stream, and issuing commands to the drug infusion device. We have designed and tested closed-loop control systems that safely and effectively regulate blood-glucose (BG) levels based on either a venous BG data stream (in diabetic pigs and in people with type 1 diabetes) or a CGM data stream (in diabetic pigs). We have further tested our CGM-based closed-loop control system in diabetic pigs using both an insulin-only configuration and a bihormonal (insulin and glucagon) configuration. Based on our positive preclinical results, we hypothesize that our CGM-based closed-loop glucose-control system can provide safe and effective BG control in people with type 1 diabetes. Our objective is to test this hypothesis and optimize our closed-loop system by conducting human trials in the Mallinckrodt Clinical Research Center at the Massachusetts General Hospital on healthy adult vol- unteers (18 years and older) with type 1 diabetes. We propose to achieve this objective with the following three specific aims: (1) to test the safety and efficacy of our control system (in both the bihormonal and insulin-only configurations) in regulating BG in adults with type 1 diabetes based on interstitial-fluid (ISF) glucose data from a CGM, (2) to repeat the study of Aim 1 using the same control system with the addition of periods of structured exercise in the study protocol, and (3) to conduct 5-day continuous closed-loop in-patient studies using a fully integrated PDA-based portable control system in adults with type 1 diabetes.

Public Health Relevance

Good, consistent management of blood sugar levels in people with type 1 diabetes is essential to prevent or minimize health complications. Our goal is to develop an engineering system that would automatically manage blood sugar in people with type 1 diabetes by developing a computer program that would link a sensing device that automatically and frequently estimates a person's blood sugar with a small pump that automatically delivers insulin to lower blood sugar. If successful, the system will provide good and safe management of blood sugar, and reduce the health complications that may arise with diabetes.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-2 (O2))
Program Officer
Arreaza-Rubin, Guillermo
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston University
Engineering (All Types)
Schools of Engineering
United States
Zip Code
Damiano, Edward R; McKeon, Katherine; El-Khatib, Firas H et al. (2014) A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum, and Enlite. J Diabetes Sci Technol 8:699-708
El-Khatib, Firas H; Russell, Steven J; Magyar, Kendra L et al. (2014) Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab 99:1701-11
Russell, Steven J; El-Khatib, Firas H; Sinha, Manasi et al. (2014) Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 371:313-325
Damiano, Edward R; El-Khatib, Firas H; Zheng, Hui et al. (2013) A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care 36:251-9
Larkin, Mary E; Beauharnais, Catherine C; Magyar, Kendra et al. (2013) Obtaining surrogate consent for a minimal-risk research study in the intensive care unit setting. Clin Trials 10:93-6
Russell, Steven J; El-Khatib, Firas H; Nathan, David M et al. (2012) Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 35:2148-55